How to Capture Growth in the Expanding Metabolic Drug Market
Overview
Bringing new metabolic disease therapies, such as GLP-1s, from a promising molecule to patient delivery requires seamless sponsor-CRDMO collaboration. In this whitepaper, Dr. Andy Lewis, Chief Scientific Officer, Dr. Andreas Reichl, Senior Drug Development Consultant, and Matthew Paterson, Chief Strategy Officer, share an inside look at what it takes to succeed in this competitive market.